Comparative clinical laboratory evaluation of leflunomide and narrow-band medium wave ultraviolet therapy for psoriasis
Year: 2015, volume 11 Issue: №3 Pages: 389-392
Heading: Dermatovenerology Article type: Short message
Authors: Nikolashina О.Е.
Organization: Penza Regional Clinical Center of specialized types of medical care
Heading: Dermatovenerology Article type: Short message
Authors: Nikolashina О.Е.
Organization: Penza Regional Clinical Center of specialized types of medical care
Summary:
Objective: to compare the clinical and laboratory evaluation of the efficacy of leflunomide and narrow-band medium wave UV therapy in patients with psoriasis. Material and methods. 60 patients with psoriasis. The patients were divided into 2 groups depending on the treatment. Patients of group 1 (30 patients) administered narrowband medium wave UV therapy — 20 procedures. Group 2 patients (30 persons) received leflunomide in combination with narrow-band medium wave UV-therapy. To evaluate the effectiveness of therapy studied cytokine profile. Results. Patients treated with leflunomide combined with phototherapy, marked a significant shift of the studied parameters and clearer resolution of lesions on the skin. Conclusion. The use of leflunomide in patients with psoriasis in combination with narrow-band medium wave UV therapy promotes a more definite resolution of psoriatic lesions on the skin and a significant improvement in quality of life, as well as the normalization of peripheral blood cytokine profile.
Keywords: clinical efficacy of therapy, cytokines, leflunomide, narrow-band medium wave UV therapy, psoriasis, T-lymphocytes
Bibliography:
1. Perlamutrov YN. Psoriasis and modern methods of treatment. Therapist 2004; (5): 38-43
2. Lench N, lies MM, Mackay I, et al. Single-point haplotype scores telomeric to human leukocyte antigen-C give a high susceptibility major histocompatability complex haplotype for psoriasis in a Caucasian population. J Invest Dermatol 2005; 124 (3): 545-552
3. Prinz JC. The role of T cells in psoriasis. Eur Acad Dermatol Venereol 2003; 17 (3): 257-270
4. Prinz JC. Which T cells cause psoriasis? Clin Exp Dermatol 1999; 24 (4): 291-295
5. Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin 2015; 33 (1): 13-23
6. Coimbra S, Figueiredo A, Castro E, et al. The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 2012; 51 (4): 389-95
7. Asiri A, Thavaneswaran A, Kalman-Lamb G, Chandran V, Gladman DD. The effectiveness of leflunomide in psoriatic arthritis. Clin Exp Rheumatol 2014; 32 (5): 728-31
8. Nash P, Tha3i D, Behrens F, Falk F, Kaltwasser JP Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 2006; 212(3): 238-49
9. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002; 41 (6): 421-30.
10. Rolla G, Ferrero N, Bergia R, Guida G. Perspectives in clinical immunology. Recenti Prog Med 2006, 97 (12): 787-96
11. Бакулев А.Л., Кравченя С.С. Об эффективности и безопасности применения клобетазола пропионата коротким курсом у больных псориазом в фазе прогрессирования. Вестник дерматологии и венерологии 2012; (3): 121-125
12. Бакулев А.Л., Кравченя С.С. Применение гепатопротекторов при псориазе: сравнительная клинико-лабораторная и ультрасонографическая оценка эффективности. Вестник дерматологии и венерологии 2010; (1): 112-117.
| Attachment | Size |
|---|---|
| 2015_03-01_389-392.pdf | 347.53 KB |
Русский
English